The Wall Street Journal: A Pillar of American Business News
Founded in 1889, The Wall Street Journal (WSJ) stands as a leading source of business and financial news in the United States and globally. As of June 2025, it maintains the largest print circulation of any newspaper in the U.S. And a substantial digital subscriber base, solidifying its position as a key publication in the media landscape.
History and Founding
The Wall Street Journal first appeared on July 8, 1889, evolving from the Kiernan News Agency. The paper was initially founded by Charles Dow, Edward Jones, and Charles Bergstresser.
Ownership and Leadership
Currently, The Wall Street Journal is published by Dow Jones & Company, which is a division of News Corp. The current publisher is Almar Latour, while Emma Tucker serves as the editor-in-chief. Other key editorial roles include Deputy Editor Charles Forelle, Managing Editor Liz Harris, and Opinion Editor Paul Gigot.
Circulation and Readership
As of 2025, The Wall Street Journal boasts a significant readership, with 4,538,000 news subscribers. This figure breaks down into 4,126,000 digital-only subscribers and 412,000 print and digital subscribers. It is the second-most subscribed digital newspaper in the nation, trailing only The New York Times.
Content and Coverage
The Wall Street Journal is renowned for its in-depth coverage of business, finance, and economic news. It is considered one of the United States’ newspapers of record. The newspaper operates on a subscription model, requiring payment for access to most of its articles and content.
Editorial Stance and Recognition
The editorial page of The Wall Street Journal generally reflects a center-right perspective. Throughout its history, the publication has been recognized for its journalistic excellence, earning 39 Pulitzer Prizes.
Unbiased News Source?
In a media landscape increasingly scrutinized for bias, The Wall Street Journal is often cited as a relatively unbiased source of news. However, it’s important to note that complete objectivity is tough to achieve, and readers should always consider multiple perspectives.
- The Rise of Illegal Coral Trafficking Amid Declining Reefs
- Green Energy and Industrial AI Accelerate in Europe
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)